Spectrum Pharmaceuticals, Inc. (SPPI) Tops Q1 EPS by 13c

April 26, 2012 9:07 AM EDT
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) reported Q1 EPS of $0.40, $0.13 better than the analyst estimate of $0.27. Revenue for the quarter came in at $60 million versus the consensus estimate of $56.93 million.

"The first quarter represents an unprecedented milestone in the history of the company, with approximately $46.5 million reported in net profits and a record EPS of $0.71," said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. "Our earnings were driven by strong pull through of FUSILEV and a judicious management of our operating expenses. I am proud that, while we are preparing to integrate two key acquisitions, we continue to be focused on growing our core business profitably. Fiscal discipline will remain a core part of our strategy, which we believe will continue to serve our shareholders well in the future."

For earnings history and earnings-related data on Spectrum Pharmaceuticals, Inc. (SPPI) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings